Document is current
Any future updates will be listed below
-
Authors
Lorenzo-Sanz, Laura http://orcid.org/0000-0001-6477-2163
Lopez-Cerda, Marta http://orcid.org/0000-0002-6511-0302
da Silva-Diz, Victoria
Artés, Marta H.
Llop, Sandra
Penin, Rosa M.
Bermejo, Josep Oriol
Gonzalez-Suarez, Eva http://orcid.org/0000-0003-0858-8171
Esteller, Manel http://orcid.org/0000-0003-4490-6093
Viñals, Francesc
Espinosa, Enrique
Oliva, Marc
Piulats, Josep M. http://orcid.org/0000-0002-3606-1724
Martin-Liberal, Juan
Muñoz, Purificación http://orcid.org/0000-0002-3751-2099
-
Funding
Funding for this research was provided by:
European Molecular Biology Organization (Short-Term Fellowship (7192))
Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya (2019FI_B_00265)
Beca GEM
- License Information
-
More Information
Article History
Received: 2 May 2023
Accepted: 17 June 2024
First Online: 24 June 2024
Competing interests
: M.E. declares research grants from Ferrer International and Incyte, and consulting fees from Quimatryx outside of this study. M.O. declares consulting or advisory arrangements with Merck, MSD and Transgene; research support (clinical trials) from Merck and Roche; that the institution receives clinical trial support from AbbVie, Ayala Pharmaceutical, MSD, ALX Oncology, Debiopharm International, Merck, ISA Pharmaceuticals, Roche Pharmaceuticals, Boehringer Ingelheim, Seagen, Gilead; and travel accommodation expenses from MSD, Merck. J.M.P. declares consulting or advisory roles for Janssen Oncology, Astellas Pharma, VCN Biosciences, Clovis Oncology, Roche/Genentech, Bristol-Myers Squibb, Merck Sharp & Dohme, BeiGene; research funding from Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Sharp & Dohme, Pfizer/EMD Serono, Incyte, Janssen Oncology; and travel, accommodation and other expenses from Janssen Oncology, Roche, Bristol-Myers Squibb. J.M.-L. has received lecturing fees from Astellas, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche, and Sanofi; advisory fees from Bristol-Myers Squibb, Highlight Therapeutics, Novartis, Pierre Fabre, Roche, Sanofi; and travel grants from Bristol-Myers Squibb, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Ipsen. All other authors declare no potential competing interests.
